Nebius will also need to take on more debt and sell more shares to fund further data center construction. Investors looking for more attractively valued AI infrastructure stocks should consider this ...
Sanofi receives an FDA CRL for tolebrutinib in nrSPMS after multiple review extensions. The EC clears Wayrilz for treating immune thrombocytopenia.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback